Canola Seed Oil (Brassica napus)

Canola seed oil (Brassica napus) is a vegetable oil rich in oleic acid (approximately 60%) and linoleic acid (approximately 20%), alongside alpha-linolenic acid (ALA), an omega-3 fatty acid. Its proposed health effects center on these unsaturated fatty acids modulating inflammatory pathways and lipid metabolism, though direct clinical trials on canola oil as a supplement remain limited.

Origin & History

Canola seed oil is a vegetable oil derived from the seeds of Brassica napus L., an annual oilseed crop primarily cultivated in Canada, the U.S., Europe, and Australia. Modern canola varieties are selectively bred to contain low erucic acid (<2%) and low glucosinolates, extracted via mechanical pressing followed by solvent extraction or advanced methods like supercritical CO₂.

Historical & Cultural Context

No historical or traditional medicinal uses of canola seed oil are documented. Canola itself emerged in the 1970s through Canadian breeding programs to develop low-erucic acid varieties from traditional rapeseed, lacking any pre-modern traditional context.

Health Benefits

• No clinical evidence available - research focuses only on extraction methods and composition
• Potential anti-inflammatory effects suggested by unsaturated fatty acid content (60-70% oleic and linoleic acids) but not clinically studied
• Possible antioxidant properties from tocopherols and phenolic compounds (sinapic acid, canolol) remain theoretical
• May support cardiovascular health through lipid modulation based on fatty acid profile, but lacks human trials
• Food-grade safety established for low-erucic varieties (<2%), unlike traditional high-erucic rapeseed

How It Works

Oleic acid in canola oil activates peroxisome proliferator-activated receptor alpha (PPAR-α), which downregulates NF-κB-mediated inflammatory gene expression and supports fatty acid oxidation. Alpha-linolenic acid (ALA, 18:3n-3) serves as a precursor to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are incorporated into cell membrane phospholipids and compete with arachidonic acid for COX and LOX enzyme activity, reducing pro-inflammatory eicosanoid synthesis. Tocopherols (vitamin E isomers) and polyphenolic compounds present in unrefined canola oil act as free radical scavengers, inhibiting lipid peroxidation via hydrogen atom transfer to peroxyl radicals.

Scientific Research

No human clinical trials, RCTs, or meta-analyses on canola seed oil for biomedical applications were found in the research. The available literature focuses exclusively on extraction methods and chemical composition rather than clinical outcomes.

Clinical Summary

Clinical research on canola oil has focused primarily on dietary substitution studies rather than supplementation trials; a 2011 randomized controlled trial (n=121) published in Nutrition, Metabolism and Cardiovascular Diseases found that replacing saturated fats with canola oil reduced LDL cholesterol by approximately 7% over 4 weeks. A meta-analysis of plant-based oils suggested ALA-rich oils like canola modestly reduce cardiovascular risk markers, but effect sizes were small and confounded by overall dietary patterns. No dedicated clinical trials have examined canola seed oil in encapsulated supplement form with standardized dosing, and evidence for anti-inflammatory or antioxidant outcomes in humans specifically from canola oil is largely inferential. Overall, the evidence base is rated as weak-to-moderate for cardiovascular lipid effects and insufficient for all other purported benefits.

Nutritional Profile

Per 100 mL of refined canola seed oil: ~884 kcal, 100 g total fat, 0 g protein, 0 g carbohydrates, 0 g fiber. Fatty acid composition: oleic acid (C18:1 ω-9) 56–65%, linoleic acid (C18:2 ω-6) 18–22%, α-linolenic acid (C18:3 ω-3) 8–12%, palmitic acid (C16:0) 3.5–5%, stearic acid (C18:0) 1–2.5%, erucic acid (C22:1) <2% (low-erucic cultivars). Favorable ω-6:ω-3 ratio of approximately 2:1. Tocopherols (vitamin E family): total 60–120 mg/100 g, predominantly α-tocopherol (~20–35 mg/100 g) and γ-tocopherol (~30–60 mg/100 g), with minor δ-tocopherol (~1–3 mg/100 g). Vitamin K₁ (phylloquinone): ~70–75 µg/100 g. Phytosterols: total 500–900 mg/100 g, primarily β-sitosterol (~350–500 mg), campesterol (~150–300 mg), and brassicasterol (~50–100 mg); phytosterols have relatively low bioavailability (~0.5–5% absorption) but competitively inhibit intestinal cholesterol absorption. Phenolic compounds (in cold-pressed/virgin canola oil): sinapic acid (~5–20 mg/100 g), canolol (vinyl syringol, a sinapic acid decarboxylation product, ~20–80 mg/100 g in roasted-seed pressed oil, negligible in fully refined oil), sinapine traces. Carotenoids: minor amounts of lutein and β-carotene (~1–3 mg/100 g in crude oil, largely removed during refining). Chlorophyll pigments: up to 5–35 ppm in crude oil, reduced to <0.025 ppm after refining. Contains no cholesterol. Trace minerals are negligible after refining. Phospholipids (lecithin): ~1–3% in crude oil, removed during degumming. Bioavailability notes: fat-soluble vitamins (E, K₁) are highly bioavailable when consumed with the oil matrix; α-linolenic acid conversion to EPA is limited (~5–10%) and to DHA is very low (<1%) in humans; oleic acid is well absorbed (>95%). Smoke point of refined canola oil: ~204–230 °C (400–446 °F), supporting stability for moderate- to high-heat cooking with minimal degradation of tocopherols at typical culinary temperatures.

Preparation & Dosage

No clinically studied dosage ranges are available as no human trials have been conducted. Commercial canola oil is typically unstandardized for bioactive compounds beyond fatty acid profiles. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Omega-3 fatty acids, vitamin E, plant sterols, olive oil, flaxseed oil

Safety & Interactions

Canola oil is generally recognized as safe (GRAS) by the FDA at typical dietary consumption levels, and adverse effects are rare; individuals with Brassica family (cruciferous vegetable) allergies should exercise caution due to potential cross-reactivity. Erucic acid, a fatty acid historically present in rapeseed oil, has been reduced to less than 2% in modern canola cultivars through selective breeding, minimizing myocardial lipidosis risk observed in animal studies. Canola oil may have an additive effect with anticoagulant medications such as warfarin due to its vitamin K and omega-3 content, potentially altering INR values, though this interaction is theoretical at supplemental doses. Pregnant and breastfeeding women consuming canola oil at dietary levels face no established risk, but high-dose supplementation lacks safety data and is not recommended.